X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.globenewswire.com/news-release/2022/10/10/2531336/30446/en/Aravive-Receives-Third-Development-Milestone-from-3D-Medicines.html
https://www.globenewswire.com/news-release/2022/09/20/2519421/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Advanced-Non-squamous-Non-Small-Cell-Lung-Cancer.html
https://www.pharmacompass.com/pdf/news/motto-international-corp-issues-voluntary-recall-of-bull-platinum-1576839037.pdf
https://www.biospace.com/article/releases/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-/?s=95
https://www.fiercepharma.com/marketing/astrazeneca-s-imfinzi-hits-survival-goal-tees-up-small-cell-lung-cancer-i-o-fight-roche
https://www.fiercebiotech.com/biotech/immunogen-cuts-deep-to-eke-out-cash-for-mirvetuximab-trial?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/roche-scores-first-global-nod-for-targeted-cancer-drug-rozlytrek
https://endpts.com/asco19-met-inhibitors-from-incyte-novartis-and-germanys-merck-face-off-for-rare-subset-of-nsclc-patients/
https://www.fiercebiotech.com/biotech/asco-shrinking-60-lung-cancers-blueprint-s-ret-drug-poised-for-2020-filing
https://www.fiercebiotech.com/biotech/asco-astellas-seattle-genetics-adc-banishes-12-urothelial-tumors
https://www.fiercepharma.com/pharma/asco-2019-what-to-watch-for-including-keytruda-lynparza-seagen-and-more
Market Place
Share 
